Hematology

Oral drug combination effective in treating newly diagnosed multiple myeloma.

According to researchers, chemotherapy parity laws ignore the real question of cost versus quality. At the same time, these laws promote anticompetitive practices that affect community oncologists.

T-cell immunotherapy enables stem cell transplants using partially mismatched family members as donors.

Bortezomib found to effectively treat chronic graft-versus-host disease.

Nanotechnology and shortwave infrared light reveals small tumors and cardiovascular lesions deep inside body.

In the pediatric hospital setting, pharmacists most frequently perform drug therapy changes on the cancer ward.

Treatment inhibits key process that enables cancer cells to multiply.

Investigational bispecific T-cell engager antibody construct aids immune system in targeting cancer cells.

The drug combination prevents nausea and vomiting after the start of cancer chemotherapy.

Brand name, patent-protected medications drive increasing costs.

In a recent phase III trial, a 3-medication regimen showed efficacy in reducing treatment-related nausea and vomiting in patients with multiple myeloma undergoing induction therapy before autologous stem cell transplant.

Thiopurines found to increase the risk of myeloid disorders.

Following favorable results of the ASPIRE clinical trial, Amgen acquired Onyx Pharmaceuticals for an estimated $9.7 billion.

A phase 2 trial reported 100% 3-year overall survival rates with frontline therapy consisting of lenalidomide, bortezomib, and dexamethasone in younger patients with multiple myeloma.

Researchers at the Dana-Farber Cancer Institute and Brigham and Women's Hospital have tested a nanomedicine technology in mice formulated to precisely target myeloma cancer cells with a novel bortezomib delivery system.

LBH589, when used in combination with bortezomib and dexamethasone, improved progression-free survival among relapsed and refractory patients with multiple myeloma.

A genetic test in development by Micromedic may help identify patients who are likely to develop bisphosphonate-associated osteonecrosis of the jaw.

Study assesses the safety and tolerability of TH-302 in combination with dexamethasone.